Efficacy and safety of LixiLan, a fixed-ratio combination of insulin glargine plus lixisenatide in type 2 diabetes not adequately controlled on basal insulin: LixiLan-L trial

被引：0
|
作者：
Aroda, V. R. [1 ]
Rosenstock, J. [2 ]
Wysham, C. [3 ]
Unger, J. [4 ]
Bellido, D. [5 ]
Galvez, G. Gonzalez [6 ]
Takami, A. [7 ]
Guo, H. [8 ]
Niemoeller, E. [9 ]
Souhami, E. [10 ]
Bergenstal, R. M. [11 ]
机构：
[1] Medstar Hlth Res Inst, Hyattsville, MD USA
[2] Dallas Diabet & Endocrine Ctr Med City, Dallas, TX USA
[3] Rockwood Clin, Spokane, WA USA
[4] Catalina Res Inst, Chino, CA USA
[5] Complejo Hosp Univ Ferrol, La Coruna, Spain
[6] Inst Jalisci Invest Diabet & Obesidad SC, Guadalajara, Jalisco, Mexico
[7] Sanofi, Tokyo, Japan
[8] BMD Consulting Inc, Somerset, NJ USA
[9] Sanofi, Frankfurt, Germany
[10] Sanofi, Paris, France
[11] Int Diabet Ctr, Minneapolis, MN USA
来源：
DIABETOLOGIA | 2016年 / 59卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
4
引用
收藏
页码：S2 / S3
页数：2
相关论文
共 50 条
  • [31] Impact of baseline glycated haemoglobin, diabetes duration and body mass index on clinical outcomes in the LixiLan-O trial testing a titratable fixed-ratio combination of insulin glargine/lixisenatide (iGlarLixi) vs insulin glargine and lixisenatide monocomponents
    Davies, Melanie J.
    Leiter, Lawrence A.
    Guerci, Bruno
    Grunberger, George
    Javier Ampudia-Blasco, F.
    Yu, Christine
    Stager, William
    Niemoeller, Elisabeth
    Souhami, Elisabeth
    Rosenstock, Julio
    DIABETES OBESITY & METABOLISM, 2017, 19 (12): : 1798 - 1804
  • [32] Clinical impact of titratable fixed-ratio combination of insulin glargine/lixisenatide vs each component alone in type 2 diabetes inadequately controlled on oral agents: LixiLan-O trial (NCT02058147).
    Rosenstock, Julio
    Aronson, Ronnie
    Hanefeld, Markolf
    Piatti, Piermarco
    Serusclat, Pierre
    Cheng, Xi
    Zhou, Tianyue
    Niemoeller, Elisabeth
    Souhami, Elisabeth
    Grunberger, George
    Davies, Melanie
    PHARMACOTHERAPY, 2016, 36 (12): : E231 - E232
  • [33] Mexican population sub-analysis of the lixilan clinical program with the fixed ratio combination of insulin glargine and lixisenatide (iGlarLixi)
    Gonzalez-Galvez, G.
    Diaz-Toscano, M. L.
    Llamas-Moreno, J. F.
    Fernandez-Rodarte, K.
    Sanudo-Maury, M. E.
    JOURNAL OF DIABETES AND ITS COMPLICATIONS, 2020, 34 (08)
  • [34] Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed-Ratio Combination vs. Insulin Glargine in Patients with T2DM: The Lixi-Lan-L Trial
    Aroda, Vanita
    Rosenstock, Julio
    Wysham, Carol
    Unger, Jeffrey
    Bellido, Diego
    Galvez, Guillermo Gonzalez
    Takami, Akane
    Guo, Hailing
    Niemoeller, Elisabeth
    Souhami, Elisabeth
    Bergenstal, Richard M.
    DIABETES, 2016, 65 : A62 - A63
  • [35] Titratable fixed-ratio combination of insulin glargine plus lixisenatide: A simplified approach to glycemic control in type 2 diabetes mellitus
    Giorgino, Francesco
    Caruso, Irene
    Napoli, Raffaele
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2020, 170
  • [36] Fixed-ratio combination of insulin glargine plus lixisenatide (iGlarLixi) improves beta cell function in people with type 2 diabetes
    Ferrannini, E.
    Boss, A.
    Dex, T.
    Servera, S.
    Mari, A.
    DIABETOLOGIA, 2021, 64 (SUPPL 1) : 261 - 262
  • [37] Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed-Ratio Combination vs. Insulin Glargine in Japanese Patients with T2DM
    Kaneto, Hideaki
    Takami, Akane
    Spranger, Robert
    Amano, Atsushi
    Watanabe, Daisuke
    Niemoeller, Elisabeth
    DIABETES, 2019, 68
  • [38] Efficacy and Safety of Insulin Glargine/Lixisenatide Fixed-Ratio Combination in Elderly Patients with T2D
    Handelsman, Yehuda
    Chovanes, Christina
    Dex, Terry
    Giorgino, Francesco
    Skolnik, Neil
    Souhami, Elisabeth
    Stager, William
    Frias, Juan Pablo
    DIABETES, 2016, 65 : A246 - A246
  • [39] Impact of dose capping in insulin glargine/lixisenatide fixed-ratio combination trials in patients with type 2 diabetes
    Schmider, Wolfgang
    Belder, Rene
    Lee, Michelle
    Niemoeller, Elisabeth
    Souhami, Elisabeth
    Frias, Juan P.
    CURRENT MEDICAL RESEARCH AND OPINION, 2019, 35 (06) : 1081 - 1089
  • [40] A Review of the Safety and Adverse Event Profile of the Fixed-Ratio Combination of Insulin Glargine and Lixisenatide
    Frias, Juan P.
    Dex, Terry
    Roberts, Michelle
    Kaplan, Allen
    DIABETES THERAPY, 2019, 10 (01) : 21 - 33
12345